Can-Fite BioPharma (NYSE:CANF) Stock Price Up 2.7% – Should You Buy?

Can-Fite BioPharma Ltd. (NYSE:CANF) shares traded up 2.7% during mid-day trading on Tuesday . The stock traded as high as $2.31 and last traded at $2.29. 168,118 shares changed hands during trading, a decline of 84% from the average daily volume of 1,076,934 shares. The stock had previously closed at $2.23.

Wall Street Analyst Weigh In

Several analysts have weighed in on CANF shares. HC Wainwright reissued a “buy” rating and set a $8.00 price objective (up from $5.00) on shares of Can-Fite BioPharma in a report on Thursday, July 2nd. D. Boral Capital upgraded shares of Can-Fite BioPharma from a “hold” rating to a “buy” rating in a research report on Wednesday, May 13th. Finally, Zacks Research raised shares of Can-Fite BioPharma to a “hold” rating in a research note on Wednesday, May 13th. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $44.00.

Can-Fite BioPharma Price Performance

The business has a 50 day moving average of $3.22 and a 200 day moving average of $3.34. The firm has a market capitalization of $1.41 million, a price-to-earnings ratio of -1.21 and a beta of 1.12.

Institutional Investors Weigh In On Can-Fite BioPharma

A hedge fund recently raised its position in Can-Fite BioPharma stock. Rhumbline Advisers grew its position in Can-Fite BioPharma Ltd. (NYSE:CANF) by 42.4% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 38,268 shares of the company’s stock after buying an additional 11,388 shares during the period. Rhumbline Advisers owned approximately 1.08% of Can-Fite BioPharma worth $57,000 at the end of the most recent quarter. Institutional investors and hedge funds own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company headquartered in Petah Tikva, Israel, that focuses on the development of small molecule drugs for the treatment of inflammatory, oncology and liver diseases. Established in 1994, the company leverages its proprietary technology platform centered on modulating the adenosine receptor system to advance novel therapeutic candidates. Can-Fite’s research and development efforts are directed toward addressing significant unmet medical needs in autoimmune and cancer indications.

The company’s lead product candidates include piclidenoson (CF101) and namodenoson (CF102).